Now available in the United States, MitraClip therapy offers a treatment option with a favorable safety profile1 to significant, symptomatic, degenerative mitral regurgitation patients who are at prohibitive risk for surgery.
MitraClip is the world's first transcatheter mitral valve repair therapy available, providing an option for select patients with degenerative MR. Clinically important results in prohibitive-risk patients with degenerative mitral regurgitation
demonstrate1,2:
→  Positive safety profile
→  Reduction in mitral regurgitation
→  Favorable left ventricular remodeling
→  Improvement in patient symptoms
→   Reduction in hospitalizations for heart failure